Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Medicilon Preclinical Research-Early Pharmacokinetics (Discovery DMPK) Team

2020-03-25
|
Page View:

Medicilon online lesson will start soon! [Cloud Archives] series will give you a detailed introduction to the lecturer’s research fields and related information. Today, let us approach Dr. Ma Fei and the early pharmacokinetic team of Medicilon!

Strictly check early and provide high-quality data
The research and development of innovative drugs is a long-term process with high investment, high risk and high return. It takes more than ten years on average from early discovery to successful listing, and the average cost is as high as more than 1 billion US dollars. Carrying out pharmacokinetic research as early as possible in the early stage of new drug development can play an important role in improving the efficiency of new drug development and reducing the risk of failure in the later stage of development.
Medicilon is one of the earliest CRO companies that launched pharmacokinetic services in China. After 16 years of development, it currently completes more than 2,000 in vivo PK studies and more than 4,000 in vitro ADME studies for domestic and foreign customers every year.
The current executive director of early pharmacokinetics, Ma Fei (Master of Chinese Pharmaceutical University, PhD in pharmacokinetics, University of Tennessee), former researcher of drug metabolism at GTx, Senior Scientist of Drug Metabolism at Seventh Wave Laboratories, and Pharmacokinetics of Shanghai Ruizhi Associate Director of Studies. Under the leadership of Dr. Ma Fei, Medicilon’s experienced and comprehensive research team provides fast and reliable Discovery DMPK services for customers from Startup to Top 10 Pharma.
Our service areas cover metabolic stability, P450 enzyme inhibition, P450 enzyme induction, enzyme phenotype analysis, protein binding rate, red blood cell/plasma partition ratio, Caco-2 permeability, transporter research, metabolite identification, reactive metabolites Screening, multi-channel administration of PK, tissue distribution and blood-brain barrier permeability, excretion studies, drug interactions in the body, multi-period cross-BE, prescription screening, etc.

High-end and complete platform, take every basic experiment seriously
Medicilon is the first new drug R&D CRO that introduced LC-MS/MS in China. In recent years, it has continuously invested heavily in the introduction of high-end equipment, and has now built:

It is represented by Sciex/Waters/Shimadzu ultra high performance liquid phase-triple quadrupole tandem mass spectrometry system (UHPLC-MS/MS), Thermo Q Exactive HF-X quadrupole/ultra-high field Fourier transform ion trap high resolution mass spectrometry Small molecule analysis instrument platform;

The macromolecule analysis instrument platform represented by MSD high-throughput multi-protein detector, Luminex liquid chip protein analysis system, Gyrolab nano-upgraded microfluidic immunoassay workstation, and Applied Biosystems real-time fluorescent quantitative PCR system;

Sample pre-processing platform represented by Covaris AFA adaptive focusing acoustic wave high-performance sample processing system, KingFisher Flex automatic magnetic bead extraction and purification system, Lysera high-efficiency sample breaker, and TurboVap high-speed sample concentrator;

A sample management platform composed of Thermo/Panasonic ultra-low temperature refrigerators, SensaTronics temperature monitoring system, and Watson LIMS laboratory information management software;
The above platforms provide strong support for early DMPK research services, pre-clinical application projects, clinical trials, and generic drug bioequivalence (BE) trials.
About Medicilon

Medicilon (stock code: 688202) is a drug development outsourcing service company (CRO). Founded on February 2, 2004, the company has gone through 16 years and established a company in Shanghai that integrates compound synthesis, compound activity screening, structural biology, pharmacodynamic evaluation, pharmacokinetic evaluation, toxicological evaluation, and formulation research A comprehensive technical service platform that conforms to international standards and is integrated with new drug registration, and has been recognized by the international drug management department. Medicipua’s animal laboratory facilities have obtained AAALAC (International Association for Animal Evaluation and Certification) certification and National Medical Products Administration NMPA GLP certification, and have reached the US Food and Drug Administration GLP standard.

Medicilon has a wealth of experience in global cooperation. Since 2015, Medicilon has served more than 500 active customers worldwide. It has served many global pharmaceutical companies such as Takeda Pharmaceuticals, Johnson & Johnson Pharmaceuticals, GlaxoSmithKline, Roche Pharmaceuticals, etc. R&D outsourcing services are provided by well-known domestic and foreign customers such as Swiss Medicine, Yangzijiang Pharmaceutical, CSPC, Huahai Pharmaceutical, and Zhongsheng Pharmaceutical.

contact us
Email: marketing@medicilon.com
Tel: +86 (21) 5859-1500

Related Articles:

Medicilon’s Metabolite Identification Services

Pharmacokinetic Research Services

Pharmacokinetic Analysis Service

Factors Affecting Pharmacokinetics of Drugs

In Vitro Drug Metabolism Studies Services

Pharmacokinetics and Pharmacodynamics (PK/PD) Studies

Medicilon Pharmacokinetic Service

Relevant newsRelevant news